• Curaleaf is pursuing an acquisition of Aurora Cannabis, issuing a fact sheet disputing Aurora’s criticism of the proposal.
• The offer implies a 45% premium; excluding Aurora cash, Curaleaf puts the premium at 110%.
• Curaleaf argues Aurora has continued issuing shares via an at-the-market program at prices below the offer’s implied value.
• Curaleaf says Aurora did not sign a confidentiality agreement or discuss price before rejecting the approach.
• The proposal includes a US$ 5 cap price; Curaleaf cites an implied premium in the 92nd percentile of Canadian M&A.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curaleaf Holdings Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202609080933CANADANWCANADAPR_C2360) on September 08, 2026, and is solely responsible for the information contained therein.